Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
Official title: Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial
Funded at University of California, San Francisco · NIH-11523068 · Data updated 2026-11-12
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 1, 2026 |
| Project end | April 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $7,400 |
| NIH project number | 3UG1EY038172-01S1 |
| Project ID | NIH-11523068 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children with juvenile idiopathic arthritis who currently have controlled anterior uveitis while on adalimumab would be the best candidates for this protocol.
✕Less likely to help
Children with recent uncontrolled uveitis, a history of rapid relapse after stopping adalimumab, or medical reasons they cannot take TNF-blockers are unlikely to benefit from dose reduction.
What this research studies
If my child joins, doctors will try reducing how much or how often they get adalimumab while watching eye exams, symptoms, and blood tests closely. Visits will include regular eye checks and monitoring so inflammation can be caught early, and adalimumab will be restarted if the uveitis flares. The goal is to find dosing that keeps the eyes quiet but lowers medication side effects and costs. The team is building on earlier work that showed many children relapse when the drug is stopped, so this approach focuses on careful dose changes rather than stopping completely.
Why it matters
Potential benefit: If successful, this could keep children's uveitis controlled with fewer drug doses, reducing side effects and lowering treatment costs.
How similar studies have gone: A prior trial (ADJUST) found high relapse rates after stopping adalimumab but that control was regained when the drug was restarted, so complete stopping proved risky and dose reduction remains less tested.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Acharya, Nisha — University of California, San Francisco
- Study coordinator: Acharya, Nisha
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
-
AI tool to standardize how uveitis is measured
This project builds an AI platform to consistently measure signs of posterior uveitis in lab models so researchers can compare and improve treatments for people with uveitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.